MicroRNA-190b Targets RFWD3 in Estrogen Receptor–Positive Breast Cancer
Background: In the year 2020, breast cancer was the most common form of cancer worldwide. Roughly 70% of breast cancers are estrogen receptor–positive (ER+). MicroRNA-190b (miR-190b) has previously been reported to be upregulated in ER+ breast cancers. Previously, we have demonstrated that miR-190b...
Main Authors: | Elisabet Alexandra Frick, Karen Kristjansdottir, Snaedís Ragnarsdottir, Arnar Ingi Vilhjalmsson, Maria Rose Bustos, Linda Vidarsdottir, Thorkell Gudjonsson, Stefan Sigurdsson |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2024-03-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.1177/11782234241234771 |
Similar Items
-
RPA, RFWD3 and BRCA2 at stalled forks: a balancing act
by: Haohui Duan, et al.
Published: (2020-11-01) -
RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
by: Ruimin Hao, et al.
Published: (2021-09-01) -
The Drosophila melanogaster Ortholog of RFWD3 Functions Independently of RAD51 During DNA Repair
by: Juan Carvajal-Garcia, et al.
Published: (2020-03-01) -
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients
by: Linda Vidarsdottir, et al.
Published: (2023-11-01) -
RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer
by: Sarah J. Taylor, et al.
Published: (2024-04-01)